Power and sample size when multiple endpoints are considered

被引:72
作者
Senn, Stephen
Bretz, Frank [1 ]
机构
[1] Novartis Pharma AG, CH-4002 Basel, Switzerland
[2] Univ Glasgow, Dept Stat, Glasgow, Lanark, Scotland
[3] Novartis Pharma AG, Basel, Switzerland
关键词
multiple testing; multiple endpoints; power;
D O I
10.1002/pst.301
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A common approach to analysing clinical trials with multiple outcomes is to control the probability for the trial as a whole of making at least one incorrect positive finding under any configuration of true and false null hypotheses. Popular approaches are to use Bonferroni corrections or structured approaches such as, for example, closed-test procedures. As is well known, such strategies, which control the family-wise error rate, typically reduce the type I error for some or all the tests of the various null hypotheses to below the nominal level. In consequence, there is generally a loss of power for individual tests. What is less well appreciated, perhaps, is that depending on approach and circumstances, the test-wise loss of power does not necessarily lead to a family wise loss of power. In fact, it may be possible to increase the overall power of a trial by carrying out tests on multiple outcomes without increasing the probability of making at least one type I error when all null hypotheses are true. We examine two types of problems to illustrate this. Unstructured testing problems arise typically (hut not exclusively) when many outcomes are being measured. We consider the case of more than two hypotheses when a Bonferroni approach is being applied while for illustration we assume compound symmetry to hold for the correlation of all variables. Using the device of a latent variable it is easy to show that power is not reduced as the number of variables tested increases, provided that the common correlation coefficient is not too high (say less than 0.75). Afterwards, we will consider structured testing problems. Here, multiplicity problems arising from the comparison of more than two treatments, as opposed to more than one measurement, are typical. We conduct a numerical study and conclude again that power is not reduced as the number of tested variables increases. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:161 / 170
页数:10
相关论文
共 50 条
  • [1] Power and Sample Size Determination in Clinical Trials with Multiple Primary Continuous Correlated Endpoints
    de Micheaux, Pierre Lafaye
    Liquet, Benoit
    Marque, Sebastien
    Riou, Jeremie
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (02) : 378 - 397
  • [2] Sample Size Determination for Equivalence Assessment with Multiple Endpoints
    Sun, Anna
    Dong, Xiaoyu
    Tsong, Yi
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (06) : 1203 - 1214
  • [3] Testing multiple primary endpoints in clinical trials with sample size adaptation
    Liu, Yi
    Hu, Mingxiu
    PHARMACEUTICAL STATISTICS, 2016, 15 (01) : 37 - 45
  • [4] Sample size determination and re-estimation for matched pair designs with multiple binary endpoints
    Xu, Jin
    Yu, Menggang
    BIOMETRICAL JOURNAL, 2013, 55 (03) : 430 - 443
  • [5] PUMP: Estimating Power, Minimum Detectable Effect Size, and Sample Size When Adjusting for Multiple Outcomes in Multi-Level Experiments
    Hunter, Kristen B.
    Miratrix, Luke
    Porter, Kristin
    JOURNAL OF STATISTICAL SOFTWARE, 2024, 108 (06): : 1 - 43
  • [6] Computing Power and Sample Size for the False Discovery Rate in Multiple Applications
    Ni, Yonghui
    Seffernick, Anna Eames
    Onar-Thomas, Arzu
    Pounds, Stanley B.
    GENES, 2024, 15 (03)
  • [7] Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan
    Sakamaki, Kentaro
    Morita, Yusuke
    Iba, Katsuhiro
    Kamiura, Toshifumi
    Yoshida, Seitaro
    Ogawa, Naoyuki
    Suganami, Hideki
    Tsuchiya, Satoru
    Fukimbara, Satoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (05) : 1097 - 1105
  • [8] Sample size determination in clinical trials with multiple co-primary binary endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    STATISTICS IN MEDICINE, 2010, 29 (21) : 2169 - 2179
  • [9] On power and sample size computation for multiple testing procedures
    Chen, Jie
    Luo, Jianfeng
    Liu, Kenneth
    Mehrotra, Devan V.
    COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2011, 55 (01) : 110 - 122
  • [10] Sample Size for Multiple Hypothesis Testing in Biosimilar Development
    Mielke, Johanna
    Jones, Byron
    Jilma, Bernd
    Koenig, Franz
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2018, 10 (01): : 39 - 49